MedTrace Logo

Does Nesiritide Provide Renal Protection

NCT01440881 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2014-06-06

Study results available
· View outcomes & findings →

Summary

This project evaluates whether nesiritide, human recombinant brain natriuretic peptide, confers renal protection during cardiovascular surgery by attenuating the inflammatory response.

Conditions

  • Renal Failure

Interventions

DRUG

Nesiritide

infuses at 0.01MCG/KG/min for 48 hours

DRUG

Placebo

infuses at 0.01MCG/KG/min for 48 hours

Sponsors & Collaborators

  • University of Florida

    lead OTHER

Principal Investigators

  • Thomas Beaver, MD · University of Florida

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01440881 on ClinicalTrials.gov